|
The Effects of Genistein on Peroxiredoxin-4 and Oxidative Stress in Lung Cancer Cell Line A549
|
R Farsiabi    , I Khodadadi , J Karimi , Gh Shafiee * |
| 1.Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, I.R.Iran. , g.r_shafiee@yahoo.com |
|
|
Abstract: (1022 Views) |
Background and Objective: Genistein is a substance from the group of isoflavones that has been reported to have anti-cancer properties in various cancers. This study was designed to investigate the effect of genistein on oxidative stress markers in lung cancer cell line A549.
Methods: In this experimental study, 0, 20, 40, 60, 80, and 100 µM genistein concentrations were used to treat A549 cells and then cell viability was measured by MTT assay after 24 and 48 hours. After selecting the IC50 dose and performing the treatment, TAC, TOS and CAT tests were measured manually and PRx4, SOD and GPx tests were measured by the kit.
Findings: The IC50 dose of genistein for A549 cells was 40 μM in 24 h. The 40 μM dose of genistein was significantly different for TAC compared with the control (0.05±0.01, 0.07±0.01 mmol/mg, respectively). However, it caused a significant increase in TOS (0.03±0.004, 0.01±0.002 mmol/mg, respectively) and OSI (0.57±0.08, 0.18±0.06, respectively) compared with the control group (p<0.05). Our results also showed that SOD (0.95±0.02, 2.56±0.19 UI/mg, respectively), CAT (0.45±0.11, 1.23±0.18 UI/mg, respectively) and PRXD4 (18.35±1.45, 42.83±3.75 pg/mg respectively) were significantly reduced in the treated groups compared to the control group (p<0.05). GPx was significantly reduced at a dose of 60 μM (85.28±4.36, 141.59±12.36 UI/mg, respectively) compared to the control group (p<0.05).
Conclusion: The results of the study showed that genistein reduces viability rate and induces oxidative stress in A549 cancer cells. |
|
| Keywords: Genistein, Oxidative Stress, A549, Lung Neoplasms. |
|
|
Full-Text [PDF 495 kb]
(176 Downloads)
|
Type of Study: Research |
Subject:
Biochemical
Received: 2023/05/31 | Accepted: 2023/10/23 | Published: 2024/09/29
|
|
|
|
|
|
|
| Send email to the article author |
|
|
